Addition of a dopamine agonist, cabergoline, to a serotonin-noradrenalin reuptake inhibitor, milnacipran as a therapeutic option in the treatment of refractory depression: two case reports
by
Takahashi H, Yoshida K, Higuchi H,
Shimizu T, Inoue T, Koyama T.
Department of Neuro-Psychiatry,
Akita University School of Medicine, Akita,
Omagari City Hospital, Omagari,
and
Department of Psychiatry,
Hokkaido University Graduate School of Medicine,
Sapporo, Japan.
Clin Neuropharmacol. 2003 Sep-Oct;26(5):230-2

ABSTRACT

SUMMARY: We illustrate 2 patients with depression who attained dramatic improvement of energy loss and fatigue when treated with cabergoline, a dopamine agonist, and milnacipran, a serotonin-noradrenalin reuptake inhibitor. Although the biologic basis of energy, motivation, and fatigue in association with depression remains unknown, some reports suggest that the decrease of noradrenalin and dopamine in the brain are particularly related to these symptoms. Therefore, treatment strategy that enhances these two monoamine neurotransmissions may be appropriate for getting a boost in energy and eliminating fatigue in patients with depression. These cases suggest that further studies are warranted to confirm the potential benefit of this strategy in the treatment of patients with depression who failed to attain complete remission due to residual symptoms including energy loss and fatigue refractory to previous treatments.

Milnacipran
Cabergoline
Dopaminergics
Cabergoline.com
Caffeine and Parkinson's disease
Cabergoline as a neuroprotectant
Dopamine agonists for Parkinson's disease
Parkinsonian signs/symptoms in depressives
Cabergoline (Dostinex ) for Parkinson's disease
Cabergoline (Dostinex) v bromocriptine (Parlodel)

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family